Identification

Name
Propranolol
Accession Number
DB00571  (APRD00194)
Type
Small Molecule
Groups
Approved, Investigational
Description

A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]

Structure
Thumb
Synonyms
  • 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
  • 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
  • beta-Propranolol
  • Propanalol
  • Propanolol
  • Propranolol
  • Propranololo
  • Propranololum
  • β-Propranolol
Product Ingredients
IngredientUNIICASInChI Key
Propranolol HydrochlorideF8A3652H1V318-98-9ZMRUPTIKESYGQW-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Detensol Tab 10mgTablet10 mgOralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Detensol Tab 120mgTablet120 mgOralDesbergers LtÉe, Division Of Technilab Inc.1981-12-311999-09-17Canada
Detensol Tab 40mgTablet40 mgOralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Detensol Tab 80mgTablet80 mgOralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Dom-propranolol TabletsTablet10 mgOralDominion Pharmacal1996-12-312016-10-25Canada
Dom-propranolol TabletsTablet40 mgOralDominion Pharmacal1996-12-312016-10-25Canada
Dom-propranolol Tablets - 80mgTablet80 mgOralDominion Pharmacal1996-12-312016-10-25Canada
HemangeolSolution4.28 mg/mLOralPierre Fabre Laboratories2014-04-14Not applicableUs
HemangiolSolution3.75 mgOralPierre Fabre Dermo Cosmetique Usa, Inc.2017-03-23Not applicableCanada
Inderal 20 Tab 20mgTablet20 mgOralAyerst Laboratories1984-12-311999-04-12Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Propranolol Tab 10mgTablet10 mgOralApotex Corporation1980-12-31Not applicableCanada
Apo Propranolol Tab 120mgTablet120 mgOralApotex Corporation1981-12-31Not applicableCanada
Apo Propranolol Tab 40mgTablet40 mgOralApotex Corporation1980-12-31Not applicableCanada
Apo Propranolol Tab 80mgTablet80 mgOralApotex Corporation1980-12-31Not applicableCanada
Apo-propranolol Tab 20mgTablet20 mgOralApotex Corporation1986-12-31Not applicableCanada
PropranololInjection1 mg/mLIntravenousGeneral Injectables & Vaccines2011-02-22Not applicableUs
PropranololInjection, solution1 mg/mLIntravenousAPP Pharmaceuticals, Inc.2001-09-07Not applicableUs
PropranololInjection1 mg/mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
PropranololTablet10 mg/1OralStat Rx USA1986-01-01Not applicableUs00591 5554 01 nlmimage10 e52172fb
Propranolol HydrochlorideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2008-10-13Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Propranolol hcl ERCapsule, extended release60 mg/1OralDirectrx2017-10-23Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralNu Care Pharmceuticals,inc.2010-06-21Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralRemedy Repack2017-11-09Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release80 mg/1OralDirectrx2017-10-27Not applicableUs
International/Other Brands
Angilol / Bedranol SR / Cardinol / Ciplar / Deralin / Dociton / Duranol / Inderal / Indobloc / INNOPRAN / Prophylux / Sumial
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Inderide-40 TabPropranolol Hydrochloride (40 mg) + Hydrochlorothiazide (25 mg)TabletOralWyeth Ayerst Canada Inc.1993-12-312001-06-05Canada
Inderide-80 TabPropranolol Hydrochloride (80 mg) + Hydrochlorothiazide (25 mg)TabletOralWyeth Ayerst Canada Inc.1993-12-312001-05-22Canada
Propranolol Hydrochloride and HydrochlorothiazidePropranolol Hydrochloride (40 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralMylan Pharmaceuticals1987-03-04Not applicableUs00378 0731 01 nlmimage10 b60e5b62
Propranolol Hydrochloride and HydrochlorothiazidePropranolol Hydrochloride (80 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralMylan Pharmaceuticals1987-04-01Not applicableUs
Propranolol ScopolaminePropranolol Hydrochloride (20 mg/20.25mg) + Scopolamine (.25 mg/20.25mg)TabletOralTPS2014-10-01Not applicableUs
Propranolol ScopolaminePropranolol Hydrochloride (40 mg/40.5mg) + Scopolamine (.5 mg/40.5mg)TabletOralTPS2014-10-01Not applicableUs
Categories
UNII
9Y8NXQ24VQ
CAS number
525-66-6
Weight
Average: 259.3434
Monoisotopic: 259.157228921
Chemical Formula
C16H21NO2
InChI Key
AQHHHDLHHXJYJD-UHFFFAOYSA-N
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
IUPAC Name
1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12

Pharmacology

Indication

For the prophylaxis of migraine.

Structured Indications
Pharmacodynamics

Propranolol, the prototype of the beta-adrenergic receptor antagonists, is a competitive, nonselective beta-blocker similar to nadolol without intrinsic sympathomimetic activity. Propanolol is a racemic compound; the l-isomer is responsible for adrenergic blocking activity.

Mechanism of action

Propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UBeta-3 adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
other/unknown
Human
U5-hydroxytryptamine receptor 1B
other/unknown
Human
Absorption

Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals.

Volume of distribution
  • 4 L
Protein binding

More than 90%

Metabolism

Hepatic

Route of elimination

Propranolol is extensively metabolized with most metabolites appearing in the urine.

Half life

4 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD50=565 mg/kg (orally in mice).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Propranolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Propranolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Propranolol.Experimental
AbirateroneThe serum concentration of Propranolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Propranolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Propranolol.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Propranolol.Approved
AcetohexamidePropranolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Propranolol is combined with Acetylcholine.Approved
AcetyldigitoxinPropranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinPropranolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Propranolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Propranolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Propranolol.Experimental, Investigational
AlaproclateThe serum concentration of Propranolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Propranolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Propranolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Propranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Propranolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Propranolol.Experimental
AlprenololPropranolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Propranolol.Approved
AmbrisentanPropranolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostinePropranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Propranolol is combined with Amiloride.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Propranolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propranolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Propranolol.Approved, Illicit
AmodiaquineThe metabolism of Propranolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Propranolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Propranolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Propranolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Propranolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Propranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Propranolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Propranolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Propranolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
AprepitantThe serum concentration of Propranolol can be increased when it is combined with Aprepitant.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Propranolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Propranolol.Approved, Investigational
ArmodafinilThe metabolism of Propranolol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propranolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Propranolol.Approved, Investigational
ArtemetherThe metabolism of Propranolol can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Propranolol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Propranolol.Approved
AtomoxetineThe metabolism of Propranolol can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Propranolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Propranolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Propranolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Propranolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Propranolol can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Propranolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Propranolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Propranolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Propranolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Propranolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Propranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Propranolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Propranolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Propranolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Propranolol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Propranolol.Approved, Withdrawn
BeractantPropranolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Propranolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Propranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Propranolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Propranolol.Experimental
BimatoprostPropranolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Propranolol.Investigational
BoceprevirThe metabolism of Propranolol can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Propranolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Propranolol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Propranolol.Approved
BQ-123Propranolol may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propranolol.Approved
BretyliumBretylium may increase the bradycardic activities of Propranolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Propranolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Propranolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Propranolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Propranolol.Investigational
BucindololPropranolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Propranolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Propranolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Propranolol is combined with Bumetanide.Approved
BunazosinPropranolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Propranolol.Approved, Investigational
BupranololPropranolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Propranolol can be decreased when combined with Bupropion.Approved
CabergolinePropranolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Propranolol.Experimental
CafedrinePropranolol may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Propranolol can be decreased when combined with Caffeine.Approved
CalfactantPropranolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Canagliflozin.Approved
CandesartanPropranolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Propranolol is combined with Candesartan cilexetil.Approved
CandoxatrilPropranolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Propranolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Propranolol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Propranolol.Approved
CarbutamidePropranolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Propranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Propranolol.Approved
CarvedilolPropranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Propranolol.Experimental
CelecoxibThe metabolism of Propranolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPropranolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Propranolol can be increased when it is combined with Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Propranolol is combined with Cevimeline.Approved
ChloramphenicolThe metabolism of Propranolol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Propranolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Propranolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Propranolol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Propranolol.Approved, Vet Approved
ChlorpropamidePropranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Propranolol.Approved
CholecalciferolThe metabolism of Propranolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineThe serum concentration of Propranolol can be decreased when it is combined with Cholestyramine.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Propranolol.Approved
CicletaninePropranolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Propranolol.Approved, Investigational
CimetidineThe metabolism of Propranolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Propranolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Propranolol can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Propranolol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Propranolol can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.Approved
ClobazamThe metabolism of Propranolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Propranolol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Propranolol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Propranolol.Approved
CloranololPropranolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Propranolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Propranolol.Approved
CobicistatThe serum concentration of Propranolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Propranolol can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Propranolol.Approved
ColesevelamThe serum concentration of Propranolol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Propranolol can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Propranolol can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Propranolol.Vet Approved
CrizotinibThe metabolism of Propranolol can be decreased when combined with Crizotinib.Approved
CryptenaminePropranolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Propranolol.Investigational
CyclopenthiazidePropranolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Propranolol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazidePropranolol may increase the hypotensive activities of Cyclothiazide.Approved
CymarinPropranolol may increase the bradycardic activities of Cymarin.Experimental
Cyproterone acetateThe serum concentration of Propranolol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Propranolol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propranolol.Approved
DabrafenibThe serum concentration of Propranolol can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Propranolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Propranolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Propranolol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Propranolol can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Propranolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Propranolol.Approved
DeferasiroxThe serum concentration of Propranolol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilPropranolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Propranolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Propranolol.Approved
DeserpidinePropranolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Propranolol.Approved
DesipramineThe metabolism of Propranolol can be decreased when combined with Desipramine.Approved
DeslanosidePropranolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Propranolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Propranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Propranolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Diclofenamide.Approved
diethylnorsperminePropranolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Propranolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Propranolol.Approved
DigitoxinPropranolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinDigoxin may increase the bradycardic activities of Propranolol.Approved
Digoxin Immune Fab (Ovine)Propranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Propranolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Propranolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Propranolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Propranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Propranolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Propranolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Propranolol.Approved
DorzolamidePropranolol may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Propranolol can be decreased when combined with Dosulepin.Approved
DoxazosinPropranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Propranolol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Propranolol.Approved, Investigational
DoxycyclineThe metabolism of Propranolol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the bradycardic activities of Propranolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Propranolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
DuloxetinePropranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Propranolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Propranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Propranolol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Propranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Propranolol.Approved
EfavirenzThe metabolism of Propranolol can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipinePropranolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Propranolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatPropranolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Propranolol.Experimental
EnzalutamideThe serum concentration of Propranolol can be decreased when it is combined with Enzalutamide.Approved
EpanololPropranolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Propranolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Propranolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Propranolol is combined with Eplerenone.Approved
EpoprostenolPropranolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Eprosartan.Approved
Ergoloid mesylatePropranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovinePropranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
ErythromycinThe metabolism of Propranolol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Propranolol can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propranolol.Approved
EsomeprazoleThe metabolism of Propranolol can be decreased when combined with Esomeprazole.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Propranolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Propranolol.Approved, Investigational
EthanolThe serum concentration of Propranolol can be decreased when it is combined with Ethanol.Approved
EthenzamideEthenzamide may decrease the antihypertensive activities of Propranolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Propranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
EtoperidoneThe serum concentration of Propranolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
EtravirineThe metabolism of Propranolol can be decreased when combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Propranolol.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Propranolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Propranolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Propranolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Propranolol.Approved
FenoldopamPropranolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Propranolol.Approved
FentanylFentanyl may increase the bradycardic activities of Propranolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Propranolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Propranolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Propranolol.Experimental
Ferulic acidPropranolol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propranolol.Approved, Investigational
FingolimodPropranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Propranolol is combined with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Propranolol can be decreased when combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Propranolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Propranolol.Experimental
FluoxetineThe metabolism of Propranolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Propranolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
FluvoxamineThe serum concentration of Propranolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Propranolol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propranolol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propranolol.Approved
FosphenytoinThe metabolism of Propranolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Propranolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Propranolol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Propranolol can be increased when it is combined with Fusidic Acid.Approved
GalantamineGalantamine may increase the bradycardic activities of Propranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Propranolol.Approved
GemfibrozilThe metabolism of Propranolol can be decreased when combined with Gemfibrozil.Approved
GitoformatePropranolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornuridePropranolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazidePropranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePropranolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePropranolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidonePropranolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepidePropranolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburidePropranolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Propranolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Propranolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Propranolol.Approved
GuanazodinePropranolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidinePropranolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
GuanoclorPropranolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPropranolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPropranolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Propranolol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Propranolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Propranolol.Experimental
HexamethoniumPropranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Propranolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Propranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Propranolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Propranolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePropranolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe metabolism of Propranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Propranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Propranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Propranolol.Approved
IloprostIloprost may increase the hypotensive activities of Propranolol.Approved, Investigational
ImatinibThe metabolism of Propranolol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Propranolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Propranolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Propranolol.Approved
IndalpineThe serum concentration of Propranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Indapamide.Approved
IndenololPropranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Propranolol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Propranolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Propranolol.Withdrawn
IndoraminPropranolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanPropranolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkPropranolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Propranolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Propranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Propranolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Propranolol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Propranolol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Propranolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Propranolol.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Propranolol can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Propranolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Propranolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Propranolol.Approved
ItraconazoleThe metabolism of Propranolol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradinePropranolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Propranolol can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Propranolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Propranolol.Investigational
KetoconazoleThe metabolism of Propranolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Propranolol.Approved
LabetalolPropranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineLacidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
LacosamidePropranolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CPropranolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotidePropranolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostPropranolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Propranolol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Propranolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Propranolol.Approved, Investigational
LevodopaPropranolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Propranolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Propranolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Propranolol.Approved, Vet Approved
LinsidominePropranolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Propranolol.Investigational
LobeglitazoneThe metabolism of Propranolol can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Propranolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Propranolol.Experimental
LopinavirThe metabolism of Propranolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Propranolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Losartan.Approved
LovastatinThe metabolism of Propranolol can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
LucinactantPropranolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Propranolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Propranolol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Propranolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
MacitentanPropranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Propranolol.Approved
MalathionMalathion may increase the bradycardic activities of Propranolol.Approved, Investigational
ManidipinePropranolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Propranolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Propranolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Propranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Propranolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Propranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Propranolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Propranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Propranolol.Approved, Investigational
MetahexamidePropranolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Propranolol.Investigational, Withdrawn
MethacholinePropranolol may increase the bronchoconstrictory activities of Methacholine.Approved
MethadoneThe metabolism of Propranolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Propranolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Propranolol.Approved
MethoserpidinePropranolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Propranolol can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Propranolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Propranolol.Approved, Investigational
MethylergometrinePropranolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Propranolol.Approved
MetildigoxinPropranolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Propranolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Propranolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propranolol.Approved, Investigational
MetyrosinePropranolol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Propranolol can be decreased when combined with Mexiletine.Approved
MibefradilPropranolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrinePropranolol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Propranolol can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Propranolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Propranolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Propranolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Propranolol.Approved
MirabegronThe metabolism of Propranolol can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Propranolol.Investigational
MitotaneThe serum concentration of Propranolol can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Propranolol.Investigational
MoclobemideThe metabolism of Propranolol can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Propranolol can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Propranolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Propranolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Propranolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Propranolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
MuzoliminePropranolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Propranolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Propranolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Propranolol.Approved
NadololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Propranolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Propranolol.Approved
NaftopidilPropranolol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Propranolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Propranolol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Propranolol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Propranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Propranolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Propranolol is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Propranolol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Propranolol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Propranolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Propranolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Propranolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Propranolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Propranolol.Approved
NiguldipinePropranolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Propranolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipinePropranolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Propranolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Propranolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Propranolol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propranolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Propranolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Propranolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Propranolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propranolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
ObinutuzumabPropranolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Propranolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Propranolol.Approved, Investigational
OlaparibThe metabolism of Propranolol can be decreased when combined with Olaparib.Approved
OleandrinPropranolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propranolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Propranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Propranolol.Approved
OmapatrilatPropranolol may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Propranolol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Propranolol.Vet Approved
OsimertinibThe serum concentration of Propranolol can be increased when it is combined with Osimertinib.Approved
OuabainPropranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Propranolol.Approved
OxprenololPropranolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Propranolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Propranolol.Approved, Vet Approved
PalbociclibThe serum concentration of Propranolol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
PanobinostatThe serum concentration of Propranolol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Propranolol can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Propranolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Propranolol.Approved
PargylinePargyline may increase the hypotensive activities of Propranolol.Approved
ParoxetineThe metabolism of Propranolol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Propranolol.Investigational
PasireotidePropranolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Propranolol.Approved
Peginterferon alfa-2bThe serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Propranolol is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Propranolol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPropranolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Propranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Propranolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Propranolol.Approved
PeruvosidePropranolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Propranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Propranolol.Withdrawn
PhenobarbitalThe metabolism of Propranolol can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePropranolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Propranolol.Withdrawn
PhentolaminePropranolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
PhenytoinThe metabolism of Propranolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Propranolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Propranolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Propranolol.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Propranolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propranolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Propranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Propranolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Propranolol.Withdrawn
Platelet Activating FactorPropranolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazidePropranolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaPropranolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Propranolol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Propranolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Propranolol.Experimental, Investigational
PrazosinPropranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Propranolol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Propranolol can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Propranolol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Propranolol.Experimental
PromazineThe metabolism of Propranolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Propranolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropafenoneThe serum concentration of Propranolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Propranolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Propranolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Propranolol.Approved, Investigational, Vet Approved
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Propranolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Propranolol.Experimental
ProscillaridinPropranolol may increase the bradycardic activities of Proscillaridin.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Propranolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Propranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Propranolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Propranolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Propranolol can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Propranolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Propranolol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Propranolol.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Propranolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Propranolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Propranolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Propranolol.Approved
RescinnaminePropranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Propranolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Propranolol.Approved, Experimental, Investigational
RifabutinThe metabolism of Propranolol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Propranolol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Propranolol can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Propranolol.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Propranolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Propranolol is combined with Riociguat.Approved
RisperidonePropranolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Propranolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabPropranolol may increase the hypotensive activities of Rituximab.Approved
RivastigminePropranolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Propranolol.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Propranolol.Investigational, Withdrawn
RolapitantThe metabolism of Propranolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Propranolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Propranolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Propranolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Propranolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Propranolol.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Propranolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Propranolol.Approved
SaprisartanPropranolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Propranolol can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Propranolol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Propranolol.Approved, Investigational, Vet Approved
SelexipagPropranolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Propranolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Propranolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Propranolol.Investigational
SertralineThe metabolism of Propranolol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Propranolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Propranolol.Approved
SiltuximabThe serum concentration of Propranolol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Propranolol can be increased when it is combined with Simeprevir.Approved
SitaxentanPropranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Propranolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Propranolol.Approved
SpiraprilPropranolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Propranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Propranolol.Investigational
St. John's WortThe serum concentration of Propranolol can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Propranolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Propranolol.Approved, Investigational
SufentanilPropranolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Propranolol.Approved
SulfisoxazoleThe metabolism of Propranolol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Propranolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Propranolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Propranolol.Experimental
TacrineTacrine may increase the bradycardic activities of Propranolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
TalinololPropranolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinPropranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Propranolol.Investigational
TelaprevirThe metabolism of Propranolol can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Propranolol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Telmisartan.Approved, Investigational
TemocaprilPropranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Propranolol.Experimental
Tenofovir disoproxilThe metabolism of Propranolol can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Propranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Propranolol.Vet Approved
TerazosinPropranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Propranolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Propranolol can be decreased when it is combined with Teriflunomide.Approved
TerlipressinPropranolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatinePropranolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Propranolol.Approved, Investigational, Withdrawn
TheodrenalinePropranolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Propranolol can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Propranolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Propranolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Propranolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Propranolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Propranolol.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propranolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Propranolol.Approved
TibolonePropranolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Propranolol can be decreased when combined with Ticlopidine.Approved
TicrynafenPropranolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Propranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Propranolol.Investigational
TipranavirThe metabolism of Propranolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Propranolol.Approved
TocilizumabThe serum concentration of Propranolol can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Propranolol.Approved, Investigational
TolazamidePropranolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePropranolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePropranolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Propranolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Propranolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Propranolol.Approved
TolonidinePropranolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Propranolol.Approved
TopiramateThe metabolism of Propranolol can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Propranolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Propranolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propranolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Propranolol.Experimental
TranylcypromineThe metabolism of Propranolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Propranolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Propranolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Propranolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Propranolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Propranolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Propranolol.Vet Approved
TrichlormethiazidePropranolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Propranolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
TrimazosinPropranolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Propranolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Propranolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Propranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
UnoprostonePropranolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilPropranolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Propranolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Propranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Propranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Propranolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Propranolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Propranolol is combined with Verapamil.Approved
VincaminePropranolol may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Propranolol.Approved, Investigational
VinpocetinePropranolol may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Propranolol can be decreased when combined with Voriconazole.Approved, Investigational
XipamidePropranolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
ZileutonThe serum concentration of Propranolol can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Propranolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Propranolol can be decreased when combined with Ziprasidone.Approved
ZofenoprilPropranolol may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Propranolol.Approved, Investigational
ZomepiracZomepirac may decrease the antihypertensive activities of Propranolol.Withdrawn
ZucapsaicinThe metabolism of Propranolol can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take with food.

References

Synthesis Reference
US3520919
General References
  1. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May;42(6):503-6. Epub 2007 Jun 22. [PubMed:17588604]
  2. Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP: Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):159-65. [PubMed:2695829]
  3. Singh N, Puri SK: Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 2000 Nov 2;77(2):185-93. [PubMed:11080509]
  4. Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K: Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006 Dec;3(12):e528. [PubMed:17194200]
External Links
Human Metabolome Database
HMDB01849
KEGG Compound
C07407
PubChem Compound
4946
PubChem Substance
46505387
ChemSpider
4777
BindingDB
25761
ChEBI
8499
ChEMBL
CHEMBL27
Therapeutic Targets Database
DAP000089
PharmGKB
PA451145
IUPHAR
564
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Propranolol
ATC Codes
C07BA05 — Propranolol and thiazidesC07AA05 — PropranololC07FA05 — Propranolol and other antihypertensives
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (256 KB)
MSDS
Download (74.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentPostural Tachycardia Syndrome1
0Not Yet RecruitingTreatmentGastrointestinal Cancers1
0RecruitingBasic ScienceMetabolic Syndromes / Normal Body Weight / Obese / Pre-Diabetic1
0RecruitingTreatmentAutism Spectrum Conditions/Disorders1
1Active Not RecruitingBasic ScienceCocaine Dependent Subjects1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableKidney Diseases1
1CompletedBasic ScienceAmylase / Heart Rate / Memory / Propanolol / Skin Electric Conductance1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics of Mirabegron1
1CompletedBasic SciencePulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticHealthy Volunteers1
1CompletedOtherTo Determine Bioequivalence Under Fed Conditions1
1CompletedTreatmentFallopian Tube Cancer / Invasive Epithelial Ovarian Cancer / Primary Peritoneal Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentProliferative Diabetic Retinopathy (PDR)1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingTreatmentPediatric Cancer1
1RecruitingTreatmentFibromyalgia Pain1
1TerminatedBasic ScienceDependence, Cocaine1
1TerminatedTreatmentSickle Cell Disorders1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
1, 2CompletedTreatmentRetinopathy of Prematurity1
1, 2Not Yet RecruitingTreatmentHemangiosarcoma1
1, 2RecruitingBasic ScienceCannabis / Post Traumatic Stress Disorder (PTSD)1
1, 2WithdrawnTreatmentDysautonomia / Traumatic Brain Injury (TBI)1
2Active Not RecruitingOtherCancer, Breast / Locally Advanced Malignant Neoplasm1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentProstatic Neoplasms1
2CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions1
2CompletedTreatmentAlcohol Dependence / PTSD1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentBrain Injury / Craniocerebral Trauma / Trauma, Nervous System / Traumatic Brain Injury (TBI)1
2CompletedTreatmentCocaine-Related Disorders2
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentHealthy Volunteers / Seasonal Affective Disorder (SAD)1
2CompletedTreatmentHemangiomas1
2CompletedTreatmentInfantile Hemangiomas1
2CompletedTreatmentMinor burns / Pain1
2CompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
2CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
2CompletedTreatmentSickle Cell Disorders1
2CompletedTreatmentStress Disorders, Traumatic, Acute1
2CompletedTreatmentSyncope1
2Not Yet RecruitingPreventionRetinopathy of Prematurity1
2Not Yet RecruitingTreatmentInduction of Labor Affected Fetus / Newborn1
2Not Yet RecruitingTreatmentPanic Disorders1
2Not Yet RecruitingTreatmentProstate Cancer1
2Not Yet RecruitingTreatmentRenal Cell Adenocarcinoma1
2Not Yet RecruitingTreatmentRetinopathy of Prematurity1
2RecruitingSupportive CareMultiple Myeloma (MM)1
2RecruitingTreatmentAcute Stress Reaction / Adjustment Disorders / Post-Traumatic Stress Disorder (PTSD) / Trauma and Stressor Related Disorders1
2RecruitingTreatmentDependence, Cocaine1
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentPost-Traumatic Stress Disorder (PTSD)1
2RecruitingTreatmentPrimary Lymphedema1
2RecruitingTreatmentRenal Angiomyolipomas / Tuberous Sclerosis1
2RecruitingTreatmentTemporomandibular Disorders1
2SuspendedTreatmentObstructive Sleep Apnea (OSA)1
2SuspendedTreatmentStage IB Skin Melanoma / Stages II Skin Melanoma / Stages III Skin Melanoma1
2TerminatedTreatmentDysfunctional Labor1
2TerminatedTreatmentHemangiomas1
2TerminatedTreatmentHemangiomas of Infancy1
2TerminatedTreatmentMetastatic Malignant Melanoma / Unresectable Malignant Melanoma1
2TerminatedTreatmentPosttraumatic Stress Disorders1
2TerminatedTreatmentTraumatic Brain Injury (TBI)1
2Unknown StatusTreatmentAsthma Bronchial1
2Unknown StatusTreatmentFeeling Anxious1
2Unknown StatusTreatmentHyperalgesia1
2Unknown StatusTreatmentPosttraumatic Stress Disorders1
2Unknown StatusTreatmentSubstance Dependence1
2WithdrawnTreatmentTraumas1
2, 3CompletedPreventionHypertension Secondary to Kidney Transplant1
2, 3CompletedPreventionStrokes1
2, 3CompletedTreatmentChronic Migraine / Migraine With Aura / Migraine Without Aura1
2, 3CompletedTreatmentInfantile Hemangiomas1
2, 3CompletedTreatmentRetinopathy of Prematurity1
2, 3CompletedTreatmentMinor burns1
2, 3Not Yet RecruitingTreatmentMelanoma1
2, 3RecruitingTreatmentAdjustment Disorders / Posttraumatic Stress Disorders / Trauma and Stressor Related Disorders1
2, 3RecruitingTreatmentDental Anxiety1
2, 3RecruitingTreatmentLiver Cirrhosis / Portal Hypertension1
2, 3RecruitingTreatmentTardive Dyskinesia1
2, 3RecruitingTreatmentMinor burns4
2, 3TerminatedTreatmentHemangioma, Capillary1
2, 3WithdrawnTreatmentRecurrent Respiratory Papillomatosis1
3CompletedOtherAnxiety Disorders1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Death, Sudden,Cardiac / Heart Diseases / Myocardial Infarction (MI) / Myocardial Ischemia / Severe ventricular arrhythmias1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedPreventionChronic Migraine1
3CompletedPreventionLiver Cirrhosis / Portal Hypertension1
3CompletedPreventionNon Cirrhotic Portal Hypertension1
3CompletedTreatmentCessation, Smoking1
3CompletedTreatmentClassic Migraine / Headaches / Migraine Without Aura / Migraines1
3CompletedTreatmentTachycardia, Supraventricular1
3RecruitingTreatmentAscites1
3RecruitingTreatmentGraves Diseases / Hyperthyroidism1
3RecruitingTreatmentHemangiomas1
3RecruitingTreatmentInfantile Hemangiomas2
3RecruitingTreatmentLiver Cirrhosis / Oesophageal varices haemorrhage / Portal Vein Thrombosis / Portal Vein, Cavernous Transformation Of1
3RecruitingTreatmentPoor; Labor1
3TerminatedPreventionLiver Cirrhosis / Varices, Esophageal1
3TerminatedTreatmentHemangiomas1
3Unknown StatusPreventionNeoplasms, Colorectal1
3WithdrawnPreventionHemorrhage, Gastrointestinal / Portal Hypertension1
4Active Not RecruitingTreatmentPostural Orthostatic Tachycardia Syndrome (POTS)1
4CompletedNot AvailableAnxiety Disorders / Posttraumatic Stress Disorders / Reconsolidation1
4CompletedDiagnosticOccupational; Cramp(s)1
4CompletedPreventionAscites / Hepatic Encephalopathy / Portal Hypertension Gastropathy / Spontaneous Bacterial Peritonitis (SBP) / Varices, Esophageal1
4CompletedPreventionGraves´ Disease1
4CompletedPreventionLiver Cirrhosis / Varices, Esophageal1
4CompletedPreventionPost-Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentEssential Vocal Tremor / Essential Voice Tremor / Tremor, Essential / Vocal Tremor / Voice Tremor1
4CompletedTreatmentHemangiomas1
4CompletedTreatmentMigrainous Headache1
4CompletedTreatmentNeurocardiogenic Syncope1
4CompletedTreatmentRapid Ventricular Response Atrial Fibrillation1
4CompletedTreatmentVestibular Migraine1
4Not Yet RecruitingBasic ScienceSmoking, Cigarette1
4Not Yet RecruitingTreatmentHyperalgesia1
4RecruitingNot AvailableObsessive-Compulsive Disorder (OCD)1
4RecruitingNot AvailableSocial Anxiety Disorder (SAD)1
4RecruitingBasic ScienceCortisol / Inflammatory Reaction / Stress, Psychological / Sympathetic Nervous System1
4RecruitingPreventionEsophageal and Gastric Varices / Hemorrhage / Liver Cirrhosis1
4RecruitingPreventionLiver Cirrhosis / Variceal Bleeding1
4RecruitingTreatmentBrain Injuries,Traumatic1
4RecruitingTreatmentVarices, Esophageal1
4TerminatedTreatmentHeadaches1
4TerminatedTreatmentPost-Traumatic Stress Disorder (PTSD)1
4TerminatedTreatmentPosttraumatic Stress Disorders1
4Unknown StatusTreatmentBleeding Gastric Varices / Liver Cirrhosis1
4Unknown StatusTreatmentGastroesophageal Varices Hemorrhage / Hepatocellular,Carcinoma1
4Unknown StatusTreatmentHepatocellular,Carcinoma / Liver Cirrhosis1
4Unknown StatusTreatmentHepatocellular,Carcinoma / Oesophageal varices haemorrhage1
4Unknown StatusTreatmentLiver Cirrhosis / Portal Hypertension1
4Unknown StatusTreatmentPost-Traumatic Stress Disorder (PTSD)1
Not AvailableActive Not RecruitingNot AvailableTremor, Essential / Tremors1
Not AvailableActive Not RecruitingPreventionBone, Age-related / Osteoporosis, Age-Related1
Not AvailableActive Not RecruitingSupportive CareCervical Cancers1
Not AvailableActive Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
Not AvailableCompletedNot AvailableHemangiomas1
Not AvailableCompletedNot AvailableHeroin Dependence / Learning and Memory1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic SciencePain Measurement1
Not AvailableCompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / High Blood Pressure (Hypertension)1
Not AvailableCompletedPreventionLiver Cirrhosis3
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation1
Not AvailableCompletedPreventionPosttraumatic Stress Disorders1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentTraumas1
Not AvailableRecruitingBasic ScienceHypoglycemia / Type1diabetes1
Not AvailableRecruitingDiagnosticDecompensated Liver Cirrhosis / Variceal Bleeding1
Not AvailableRecruitingDiagnosticPostural Orthostatic Tachycardia Syndrome (POTS) / Tachycardia1
Not AvailableRecruitingPreventionPost-Traumatic Stress Disorder (PTSD)1
Not AvailableRecruitingTreatmentAutism, Early Infantile1
Not AvailableRecruitingTreatmentGastric Varix / Liver Cirrhoses / Portal Hypertension1
Not AvailableRecruitingTreatmentHepatic Cirrhosis / Liver Cirrhoses1
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma / Male Breast Cancer / Recurrent Melanoma / Stage IV Breast Cancer / Stage IV Melanoma / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Portal Vein Thrombosis1
Not AvailableRecruitingTreatmentPortal Hypertension2
Not AvailableRecruitingTreatmentRetinopathy of Prematurity1
Not AvailableRecruitingTreatmentMinor burns1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusBasic ScienceMyofascial Temporomandibular Disorders / Temporomandibular Joint Disorders1
Not AvailableUnknown StatusHealth Services ResearchMigraines1
Not AvailableUnknown StatusPreventionGastric Diseases / Migrainous Headache1
Not AvailableUnknown StatusPreventionPrimary Operable Breast Cancer1
Not AvailableUnknown StatusTreatmentDependence, Cocaine1
Not AvailableUnknown StatusTreatmentPosttraumatic Stress Disorders / Traumatic Memory1
Not AvailableWithdrawnTreatmentAutism, Early Infantile1

Pharmacoeconomics

Manufacturers
  • Akrimax pharmaceuticals llc
  • Glaxosmithkline llc
  • Actavis elizabeth llc
  • Inwood laboratories inc sub forest laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical
  • Upsher smith laboratories inc
  • Roxane laboratories inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Sandoz canada inc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Morton grove pharmaceuticals inc
  • Wyeth ayerst laboratories
  • Clonmel healthcare ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Interpharm inc
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Northstar healthcare holdings ltd
  • Par pharmaceutical inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Schering corp sub schering plough corp
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals
  • Warner chilcott div warner lambert co
  • Warner chilcott inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
SolutionOral4.28 mg/mL
SolutionOral3.75 mg
LiquidIntravenous1 mg
Capsule, extended releaseOral160 mg/1
Capsule, extended releaseOral60 mg/1
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral160 mg
Capsule, extended releaseOral60 mg
Capsule, extended releaseOral80 mg
Capsule, extended releaseOral120 mg/1
TabletOral120 mg
InjectionIntravenous1 mg/mL
Injection, solutionIntravenous1 mg/mL
SolutionOral20 mg/5mL
SolutionOral40 mg/5mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral50 mg/1
TabletOral60 mg/1
TabletOral80 mg/1
Capsule, extended releaseOral80 mg/1
SolutionIntravenous1 mg
TabletOral10 mg/301
TabletOral
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Propranolol hcl powder11.63USD g
Propranolol 1 mg/ml vial10.0USD ml
Inderal la 160 mg capsule8.41USD capsule
Inderal LA 160 mg 24 Hour Capsule7.6USD capsule
Inderal la 160 mg capsule sa7.01USD capsule
Inderal la 120 mg capsule6.42USD capsule
Inderal LA 120 mg 24 Hour Capsule5.8USD capsule
Inderal la 120 mg capsule sa5.36USD capsule
Inderal la 80 mg capsule5.18USD capsule
Inderal LA 60 mg 24 Hour Capsule4.79USD capsule
Inderal LA 80 mg 24 Hour Capsule4.68USD capsule
Inderal la 60 mg capsule4.43USD capsule
Inderal la 80 mg capsule sa4.32USD capsule
Inderal la 60 mg capsule sa3.7USD capsule
Propranolol HCl CR 160 mg 24 Hour Capsule2.62USD capsule
InnoPran XL 80 mg 24 Hour Capsule2.5USD capsule
InnoPran XL 120 mg 24 Hour Capsule2.46USD capsule
Innopran xl 120 mg capsule2.41USD capsule
Innopran xl 80 mg capsule2.41USD capsule
Inderide 80-25 mg tablet2.17USD tablet
Propranolol HCl CR 120 mg 24 Hour Capsule2.0USD capsule
Inderide 40-25 mg tablet1.74USD tablet
Propranolol HCl CR 80 mg 24 Hour Capsule1.61USD capsule
Propranolol HCl CR 60 mg 24 Hour Capsule1.38USD capsule
Propranolol HCl 60 mg tablet1.27USD tablet
Inderal-La 160 mg Sustained-Release Capsule1.26USD capsule
Inderal-La 120 mg Sustained-Release Capsule1.07USD capsule
Inderal-La 80 mg Sustained-Release Capsule0.69USD capsule
Propranolol HCl 80 mg tablet0.66USD tablet
Propranolol-HCTZ 80-25 mg tablet0.65USD tablet
Inderal-La 60 mg Sustained-Release Capsule0.62USD capsule
Propranolol-HCTZ 40-25 mg tablet0.61USD tablet
Propranolol 80 mg tablet0.58USD tablet
Propranolol 60 mg tablet0.56USD tablet
Propranolol HCl 40 mg tablet0.53USD tablet
Propranolol 40 mg tablet0.45USD tablet
Propranolol HCl 20 mg tablet0.36USD tablet
Propranolol 20 mg tablet0.33USD tablet
Apo-Propranolol 120 mg Tablet0.32USD tablet
Propranolol HCl 10 mg tablet0.29USD tablet
Propranolol 10 mg tablet0.22USD tablet
Propranolol HCl 20 mg/5ml Solution0.11USD ml
Apo-Propranolol 80 mg Tablet0.06USD tablet
Novo-Pranol 80 mg Tablet0.06USD tablet
Pms-Propranolol 80 mg Tablet0.06USD tablet
Apo-Propranolol 20 mg Tablet0.04USD tablet
Apo-Propranolol 40 mg Tablet0.04USD tablet
Novo-Pranol 20 mg Tablet0.04USD tablet
Novo-Pranol 40 mg Tablet0.04USD tablet
Apo-Propranolol 10 mg Tablet0.02USD tablet
Novo-Pranol 10 mg Tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6500454No2001-10-042021-10-04Us
US8338489No2008-10-162028-10-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)96 °CPhysProp
water solubility61.7 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.48AVDEEF,A (1997)
Caco2 permeability-4.58ADME Research, USCD
pKa9.42SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0794 mg/mLALOGPS
logP3.03ALOGPS
logP2.58ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity76.83 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier-0.9031
Caco-2 permeable+0.6942
P-glycoprotein substrateSubstrate0.7079
P-glycoprotein inhibitor IInhibitor0.5588
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6463
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.924
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8487
Ames testNon AMES toxic0.9392
CarcinogenicityNon-carcinogens0.9097
BiodegradationNot ready biodegradable0.9871
Rat acute toxicity2.5625 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9185
hERG inhibition (predictor II)Inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-03di-0090000000-f8c39664b694f5784865
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-05fr-9000000000-84923a2dc3053801527a
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0fk9-2932000000-fa245a17a643ef33a0b2
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-03di-0090000000-ee9d9c871e322202a948
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-03di-0290000000-9f3f72a6b6b792659137
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-0avi-5900000000-95293e6a5f843d0cc282
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-0ab9-9700000000-6b5b9e9743cb3f7bca58
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-0adi-9700000000-f5825268222d45a4ce95
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0159-1900000000-9872255282c6a95633aa
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00di-9500000000-122203085c028de6cbe4
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0aor-0900000000-39e75b6ae19b4763a0bf
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-004i-0900000000-b75e7bf7aa20ce854157
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00di-9200000000-2f102916e2fe0f6c1f4b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0c00-9650000000-c4a4f189be72c438d080
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0910000000-d7db5bab374a7cf02fd3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-057a63162f5e674c4ce6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0190000000-87c354c205b94f5f06e1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0cl0-4930000000-1eecec66280a12a94b9d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ab9-4900000000-ddd58df17ce1f65a7559
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-4900000000-711c94a7c2e5c24e9e84
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a6r-3900000000-54967b29c739db5eb0d5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-057a63162f5e674c4ce6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0190000000-f4e36c8dd4e96992c94d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0830-4920000000-835447ce35e37ab07193
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ab9-5900000000-25248a6b39724a02096d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-4900000000-5663a764e73595039671
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a6r-3900000000-20d14f48fc5615796a2d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0910000000-d51a9e2266c2de91bfaa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0090000000-d6c29037a12e6224fc5c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-3590000000-e89d2a443f5d3480df83
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0avi-7900000000-073897b09869caa5bcdc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-7900000000-566e620bc2a178d2a8e7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-6900000000-21115e5f6c969e2f9e0f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0adi-5900000000-c8d935c939307db2ee51
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0090000000-ee9d9c871e322202a948
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0290000000-53507ada5020c820cd0f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0avi-5900000000-95293e6a5f843d0cc282
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0ab9-9700000000-264398d3bc59c8ced5ed
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0adi-9700000000-f5825268222d45a4ce95
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0159-1900000000-63f0b6b57a76617acc2d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-060r-4900000000-c1976ec4cf413372eb24
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05i0-4900000000-dfc2a11c8d505e07028b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0900000000-ece05c33751eecfe1c79
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0900000000-cbbd556232c991733f57
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-4590000000-aaddd1419df983db1236
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Naphthalene / Alkyl aryl ether / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Ether / Secondary amine / Organic nitrogen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
secondary amine, propanolamine, naphthalenes (CHEBI:8499)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Lewis CJ, Gong H, Brown MJ, Harding SE: Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology. Br J Pharmacol. 2004 Mar;141(5):813-24. Epub 2004 Feb 2. [PubMed:14757703]
  3. Rouget C, Barthez O, Goirand F, Leroy MJ, Breuiller-Fouche M, Rakotoniaina Z, Guerard P, Morcillo EJ, Advenier C, Sagot P, Cabrol D, Dumas M, Bardou M: Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia. Biol Reprod. 2006 Jan;74(1):209-16. Epub 2005 Sep 21. [PubMed:16177222]
  4. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
  5. Rezmann-Vitti LA, Louis SN, Nero TL, Jackman GP, Machida CA, Louis WJ: Site-directed mutagenesis of the rat beta1-adrenoceptor. Involvement of Tyr356 (7.43) in (+/-)cyanopindolol but not (+/-)[125Iodo]cyanopindolol binding. Eur J Med Chem. 2004 Jul;39(7):625-31. [PubMed:15236843]
  6. Yazawa K, Wang JW, Hao LY, Onoue Y, Kameyama M: Verrucotoxin, a stonefish venom, modulates calcium channel activity in guinea-pig ventricular myocytes. Br J Pharmacol. 2007 Aug;151(8):1198-203. Epub 2007 Jun 18. [PubMed:17572694]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Isaza C, Henao J, Ramirez E, Cuesta F, Cacabelos R: Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Methods Find Exp Clin Pharmacol. 2005 May;27(4):237-44. [PubMed:16082424]
  2. Rouget C, Barthez O, Goirand F, Leroy MJ, Breuiller-Fouche M, Rakotoniaina Z, Guerard P, Morcillo EJ, Advenier C, Sagot P, Cabrol D, Dumas M, Bardou M: Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia. Biol Reprod. 2006 Jan;74(1):209-16. Epub 2005 Sep 21. [PubMed:16177222]
  3. Illingworth CJ, Gooding SR, Winn PJ, Jones GA, Ferenczy GG, Reynolds CA: Classical polarization in hybrid QM/MM methods. J Phys Chem A. 2006 May 25;110(20):6487-97. [PubMed:16706406]
  4. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Berg T, Piercey BW, Jensen J: Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension. 2010 May;55(5):1224-30. doi: 10.1161/HYPERTENSIONAHA.109.149286. Epub 2010 Mar 15. [PubMed:20231523]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Smejkal-Jagar L, Boranic M: Serotonin and serotoninergic agents affect proliferation of normal and transformed lymphoid cells. Immunopharmacol Immunotoxicol. 1995 Feb;17(1):151-62. [PubMed:7759768]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Bailey SR, Elliott J: Evidence for different 5-HT1B/1D receptors mediating vasoconstriction of equine digital arteries and veins. Eur J Pharmacol. 1998 Aug 21;355(2-3):175-87. [PubMed:9760032]
  2. Choppin A, O'Connor SE: Presence of vasoconstrictor 5HT1-like receptors revealed by precontraction of rabbit isolated mesenteric artery. Br J Pharmacol. 1995 Jan;114(2):309-14. [PubMed:7881730]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. [PubMed:7640150]
  2. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619]
  3. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659]
  6. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15. [PubMed:7895609]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
2. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. [PubMed:7640150]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  2. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18